Incyte Corp_ office sign-by Bo Shen via iStock Sohini Mondal Tue, January 13, 2026 at 10:03 PM GMT+8 2 min read In this article: - INCY +2.44%
With a market cap of $20.9 billion, Incyte Corporation (INCY) is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapeutics across the United States, Europe, Canada, and Japan. It markets a diverse portfolio of oncology, immunology, and dermatology medicines, including JAKAFI, OPZELURA, and ICLUSIG.
The Wilmington, Delaware-based company is set to unveil its fiscal Q4 2025 results soon. Ahead of this event, analysts expect INCY to report a profit of $1.66 per share, up 52.3% from $1.09 per share in the year-ago quarter. It has surpassed Wall Street's bottom-line estimates in three of the past four quarters while missing on another occasion.
More News from Barchart
-
As Trump Says He Is ‘Proud’ of Intel, Should You Buy INTC Stock?
-
As SanDisk Eyes Doubling Memory Prices, Should You Buy Red-Hot SNDK Stock?
-
As Netflix Drops 33%, Is NFLX Stock Buy Ahead of Q4 Earnings?
-
Stop Missing Market Moves: Get the FREE Barchart Brief – your midday dose of stock movers, trending sectors, and actionable trade ideas, delivered right to your inbox. Sign Up Now!
For fiscal 2025, analysts forecast the specialty drugmaker to post EPS of $5.86, a significant surge from $0.08 in fiscal 2024.
www.barchart.com INCY stock has soared 50.7% over the past 52 weeks, outperforming the broader S&P 500 Index's ($SPX) 19.7% gain and the State Street Health Care Select Sector SPDR ETF's (XLV) 12.7% return over the same period.
www.barchart.com Incyte reported strong Q3 2025 results on Oct. 28 that beat expectations, with adjusted EPS of $2.26 and total revenue of $1.37 billion, up 20% year-over-year. Investor sentiment was further boosted by robust product performance, including Jakafi revenue of $791 million, Opzelura revenue of $188 million, and strong early uptake of Niktimvo with $46 million in sales. Additionally, Incyte raised its full-year 2025 net product revenue guidance to $4.23 billion - $4.32 billion. Nevertheless, the stock fell 1.5% on that day.
Analysts' consensus rating on INCY stock is cautiously optimistic, with a "Moderate Buy" rating overall. Out of 25 analysts covering the stock, opinions include 12 "Strong Buy,” 12 "Holds,” and one "Strong Sell.” This configuration is slightly more bullish than three months ago, with 11 analysts suggesting a "Strong Buy." As of writing, it is trading above the average analyst price target of $102.09.
On the date of publication, Sohini Mondal did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com
條款 及 私隱政策 Privacy Dashboard More Info